| MINE-ESHAP联合方案治疗难治或复发性非霍奇金淋巴瘤28例 |
| |
| 引用本文： | 冯国安,邢正云. MINE-ESHAP联合方案治疗难治或复发性非霍奇金淋巴瘤28例[J]. 白血病．淋巴瘤, 2009, 19(10): 363-364. DOI: 10.3760/cma.j.issn.1009-9921.2010.06.015 |
| |
| 作者姓名： | 冯国安 邢正云 |
| |
| 作者单位： | 江苏省大丰市人民医院血液肿瘤科,224100; |
| |
| 摘 要： | 目的 探讨MINE-ESHAP联合方案治疗难治性或复发性非霍奇金淋巴瘤(NHL)的疗效.方法 采用MINE-ESHAP联合方案治疗难治性或复发性NHL 28例.结果 28例患者中,CR 11例(39.3%),PR 6例(21.4%),SD 5例(17.9%),进展或恶化5例(17.9%),中位生存时间28.5个月.1例死于骨髓抑制期感染(3.6%).不良反应主要为消化道症状和骨髓抑制.结论 MINE-ESHAP方案对部分难治性或复发性NHL患者有效,不良反应可以耐受,可用于对其他化疗方案无效的难治性或复发性NHL.
|
| 关 键 词： | 淋巴瘤,非霍奇金 抗肿瘤联合化疗方案 疗效 |
Effect of MINE-ESHAP regimen in treatment of refractory or relapsed non-Hodgkin lymphoma |
| |
| Abstract: | Objective To evaluate the efficacy of MINE-ESHAP regimen in treatment of refractory and relapsed non-Hodgkin lymphoma (NHL). Methods Twenty-eight patients with refractory and relapsed NHL were treated with MINE-ESHAP regimen. Results The rate of complete remission was 39.3 %(11/28),of partial remission 21.4 %(6/28),of stable disease 17.9 %(5/28),and of progression 17.94 %(5/28). The midsurvival time was 28.5 months. One patient died of infection during marrow restrain period. The main toxicities included gastrointestinal symptoms and myelosuppression. Conclusion MINE-ESHAP regimen is sate and could be employed in treatment of the patients with refractory and relapsed NHL. |
| |
| Keywords: | Lymphoma non-HodgkinAntineoplastic combined chemotherapy protocolsOutcome |
|
|
